ENTITY
Telix Pharmaceuticals

Telix Pharmaceuticals (TLX AU)

27
Analysis
Health CareAustralia
Telix Pharmaceuticals Limited operates as a biotechnology company. The Company develops and commercializes molecularly-targeted radiation therapy for the treatment of prostate, renal, and brain cancer. Telix Pharmaceuticals serves patients worldwide.
more
Refresh
05 Nov 2020 15:38Issuer-paid

Telix Pharmaceuticals - Telix signs a big China deal

Telix announced on 2 November 2020 that it has entered into a licensing agreement with China Grand Pharmaceutical (CGP) for the greater Chinese...

Share
28 Sep 2020 21:20Issuer-paid

Telix Pharmaceuticals - TLX591-CDx NDA submitted

On 24 September 2020 Telix announced it had submitted its NDA to the FDA for approval of TLX591-CDx, its positron emission tomography (PET) imaging...

Share
08 Sep 2020 20:54Issuer-paid

Telix Pharmaceuticals - A look at future directions

For the first time, Telix provided a profile of its deep pipeline outside its lead asset on its H120 earnings call. It presented the details of...

Share
02 Jul 2020 20:42Issuer-paid

Telix Pharmaceuticals - Major developments coming up

We expect 2020 to be a major turning point for Telix Pharmaceuticals. The regulatory submissions for illumet will determine whether the company...

Share
07 May 2020 14:46Issuer-paid

Telix Pharmaceuticals - Making progress despite headwinds

The NDA submission for illumet has been delayed slightly by COVID-19 but is expected to be submitted in Q220 (from March-April guidance). A...

Share
x